Stock listing

NASDAQ:PYXS Pyxis Oncology, Inc. Stock

Home listing (NASDAQ) of Pyxis Oncology, Inc.

Follow Pyxis Oncology, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:PYXS

$1.81 USD +0.13 (+7.7%)

Close on Nov 20, 2026

Past year -60.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.70 – $1.99 USDNov 20, 2026
Volume
3.05M sharesNov 20, 2026
Market cap
$216.5M USDAt the close on Nov 20, 2026 · price × 119.6M shares outstanding
52-week range
$1.03 – $5.55 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$2.51M USDMedian day 729,200 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Pyxis Oncology, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:PYXS · Home$1.81 USD+0.13 (+7.7%)3,046,358$1.70$1.99$1.70$1.68Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:PYXS · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.81+0.13+7.7%$1.70$1.99$1.703,046,358
$1.68+0.27+19.1%$1.41$1.695$1.351,804,987
$1.41-0.03-2.1%$1.45$1.48$1.38765,152
$1.44+0.03+2.1%$1.48$1.53$1.341,435,539
$1.41-0.17-10.8%$1.55$1.56$1.41847,998
$1.580.000.0%$1.57$1.60$1.51359,400
$1.58-0.06-3.7%$1.62$1.625$1.521,003,100
$1.64+0.01+0.6%$1.63$1.68$1.59665,200
$1.63-0.07-4.1%$1.66$1.735$1.59592,600
$1.70+0.04+2.4%$1.70$1.795$1.67880,900
$1.66+0.05+3.1%$1.62$1.74$1.62560,400
$1.61-0.05-3.0%$1.64$1.675$1.501,149,600
$1.66+0.02+1.2%$1.67$1.71$1.565923,000
$1.64-0.05-3.0%$1.72$1.76$1.62645,800
$1.69-0.12-6.6%$1.825$1.86$1.625897,200
$1.81-0.08-4.2%$1.88$1.885$1.78685,700
$1.89-0.09-4.5%$1.98$1.992$1.88697,200
$1.98+0.14+7.6%$1.83$1.99$1.80728,100
$1.84+0.15+8.9%$1.70$1.85$1.681,183,200
$1.69+0.01+0.6%$1.66$1.72$1.634645,800
$1.68-0.03-1.8%$1.70$1.71$1.63626,700
$1.71-0.05-2.8%$1.74$1.79$1.695557,500
$1.76-0.08-4.3%$1.85$1.87$1.75500,400
$1.84+0.08+4.5%$1.76$1.90$1.731,110,300
$1.76+0.08+4.8%$1.69$1.79$1.6751,016,400
$1.68-0.12-6.7%$1.79$1.79$1.66908,200
$1.80+0.01+0.6%$1.79$1.84$1.75545,700
$1.79-0.06-3.2%$1.82$1.88$1.7351,558,200
$1.85-0.16-8.0%$1.99$1.998$1.85900,400
$2.01-0.02-1.0%$2.03$2.08$1.99505,700
$2.03+0.04+2.0%$1.99$2.06$1.98950,400
$1.99-0.02-1.0%$2.03$2.03$1.9021,097,100
$2.01-0.01-0.5%$2.02$2.086$2.00957,800
$2.02-0.22-9.8%$2.22$2.22$2.001,403,400
$2.24+0.10+4.7%$2.12$2.26$2.051,515,100
$2.14-0.05-2.3%$2.21$2.31$2.101,996,600
$2.19-0.14-6.0%$2.31$2.31$2.192,602,300
$2.33-0.57-19.7%$2.375$2.41$2.128,149,500
$2.900.000.0%$2.94$2.94$2.83335,500
$2.90+0.04+1.4%$2.81$2.91$2.75368,100
$2.86-0.06-2.1%$2.91$2.92$2.785609,700
$2.92-0.30-9.3%$3.22$3.25$2.86875,300
$3.22-0.135-4.0%$3.36$3.36$3.20433,600
$3.355+0.165+5.2%$3.21$3.405$3.19479,800
$3.19-0.14-4.2%$3.38$3.38$3.19632,800
$3.33-0.08-2.3%$3.38$3.44$3.33563,900
$3.41+0.07+2.1%$3.43$3.472$3.339476,700
$3.34+0.01+0.3%$3.34$3.42$3.32639,900
$3.33-0.10-2.9%$3.40$3.42$3.24489,600
$3.43+0.22+6.9%$3.21$3.515$3.21699,500
$3.21-0.06-1.8%$3.31$3.42$3.071,129,400
$3.27-0.11-3.3%$3.42$3.437$3.18738,500
$3.38-0.51-13.1%$3.48$4.12$3.1324,345,200
$3.890.000.0%$4.00$4.15$3.8451,375,600
$3.89+0.325+9.1%$3.53$4.05$3.5152,230,600
$3.565-0.185-4.9%$3.71$3.74$3.45812,100
$3.75+0.31+9.0%$3.45$3.77$3.435730,300
$3.44+0.20+6.2%$3.24$3.57$3.18590,200
$3.24+0.01+0.3%$3.20$3.28$3.05469,500
$3.23-0.09-2.7%$3.32$3.38$3.20212,000
$3.32-0.02-0.6%$3.31$3.37$3.23396,700
$3.34+0.28+9.2%$3.03$3.36$3.00634,200
$3.06+0.10+3.4%$2.96$3.09$2.94422,221
$2.96-0.12-3.9%$3.02$3.07$2.825837,591
$3.08-0.04-1.3%$3.15$3.21$3.02682,100
$3.12-0.25-7.4%$3.30$3.39$3.03716,100
Ticker
NASDAQ:PYXS
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Pyxis Oncology, Inc. news

Pyxis Oncology, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
19 in the last 12 months · 83 in all · newest Nov 18, 2026 · oldest 2021
Decks
13 decks · latest Sep 9, 2026

Where Pyxis Oncology, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:PYXS · Home listing · This pageNASDAQUnited StatesUSD
BOATS:PYXSBOATSUnited StatesUSD

Valuation

Price/book 5.2× against a median of 1.4×: the highest of 9 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$160.9M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
5.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
0.89

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Pyxis Oncology, Inc. · NASDAQ:PYXSUS$216.5MUS$160.9Mn/an/an/a5.2×n/a0.0×0.89
Northwest Biotherapeutics, Inc. · OTC:NWBOUS$220.0MUS$283.8Mn/a99.4×n/an/an/an/a0.90
Keros Therapeutics, Inc. · NASDAQ:KROSUS$219.7M−US$24.67Mn/a−0.6×n/a0.8×−152.7%0.1×1.16
Immuneering Corporation · NASDAQ:IMRXUS$218.7MUS$160.5Mn/an/an/a1.3×n/a0.0×1.17
Allogene Therapeutics, Inc. · NASDAQ:ALLOUS$217.5M−US$7.44Mn/a−1.6×n/a0.6×n/a0.2×1.93
ProKidney Corp. · NASDAQ:PROKUS$217.3MUS$77.56Mn/a100×n/an/an/an/a1.61
Oryzon Genomics SA · BME:ORYUS$216.4MUS$206.7Mn/an/an/a1.6×n/a0.1×n/a
Rocket Pharmaceuticals, Inc. · NASDAQ:RCKTUS$214.1M−US$25.02Mn/an/an/a0.7×n/a0.1×1.72
Orum Therapeutics, Inc. · KRX:475830US$212.5MUS$24.22M15.4×n/an/a1.5×n/a0.0×n/a
GemVax & KAEL Co Ltd · KRX:082270US$212.3MUS$207.4Mn/a3.3×21.2×3.8×−14.4%0.4×n/a
Transgene SA · EURONEXT:TNGUS$212.2MUS$112.7Mn/a750×n/a1.8×n/a0.0×n/a
Median of the othersUS$216.8MUS$95.15M15.4×51.3×21.2×1.4×−83.5%0.1×1.39

Forecasts

8 strong buy · 1 hold · Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.

Price target
8.56 USD · Analysts' mean
EPS, year to Dec 2026
-1.13 · 9 analysts

Team and board

Officers

OfficerRole
Thomas CivikChief Executive Officer and Chairman of the Board
Nelson AzoulayChief Business Officer

Board

DirectorRole
Thomas CivikChief Executive Officer and Chairman of the Board
Darren ClineDirector
Freda Lewis-HallDirector
Jakob DupontDirector
John FlavinLead Independent Director
Michael A. MetzgerDirector
Rachel HumphreyDirector

Events

QuarterResultsShare move
Q3 2026Nov 5, 2026 · Before open−3.0%
Q2 2026Aug 13, 2026 · Before open−5.3%
Q1 2026May 14, 2026 · Before open−15.7%
Q4 2025Mar 25, 2026+2.2%
Q3 2025Nov 3, 2025 · Before open+7.0%
Q2 2025Aug 14, 2025 · After close+8.8%
Q1 2025May 15, 2025 · Before open+3.7%
Q4 2024Mar 19, 2025+5.7%
Q3 2024Nov 12, 2024 · Before open−2.5%
Q2 2024Aug 14, 2024 · After close+2.1%
All 20 quarters
QuarterResultsShare move
Q1 2024May 14, 2024 · Before open−2.1%
Q4 2023Mar 21, 2024 · Before open−8.7%
Q3 2023Nov 7, 2023 · After close−1.8%
Q2 2023Aug 11, 2023 · Before open+6.6%
Q1 2023May 11, 2023 · Before open+2.0%
Q4 2022Mar 22, 2023 · Before open0.0%
Q3 2022Nov 1, 2022 · Before open−9.6%
Q2 2022Aug 15, 2022 · Before open−4.5%
Q1 2022May 13, 2022 · Before open−9.0%
Q4 2021Mar 29, 2022 · Before open+0.6%

Open Events

Decks

DeckKindSlidesDate
Corporate Update (September 2026)Corporate update33 slidesSep 9, 2026
Investor Presentation (March 2026)Investor deck43 slidesMar 23, 2026
Corporate Update (December 2025)Corporate update29 slidesDec 18, 2025
Investor Presentation (November 2025)Investor deck31 slidesNov 3, 2025
Corporate Update (March 2025)Corporate update29 slidesMar 18, 2025
Technical Presentation (November 2024)Technical40 slidesNov 20, 2024
Investor Presentation (March 2024)Investor deck33 slidesMar 21, 2024
Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022Conference25 slidesNov 10, 2022
ASCO 2022Conference14 slidesJune 2022
Technical Presentation (April 2022)Technical21 slidesApril 2022
All 13 decks
DeckKindSlidesDate
Technical Presentation (December 2020)Technical10 slidesDecember 2020
AACR Annual Meeting 2019Conference25 slidesMar 31, 2019
SITC 32nd Annual Meeting 2017Conference19 slidesNovember 2017

Open Decks

Financings

RaiseDate
Public offering of common stock or pre-funded warrants with accompanying common warrants
Closed: US$110M raised · US$2.9 a share · Warrants at US$3.5 · Leerink Partners +2
Dealers: Leerink Partners (co-lead), Guggenheim Securities (co-lead), Wells Fargo Securities (co-lead)
Buyers: OrbiMed; GordonMD Global Investments; BVF Partners; Coastlands Capital; RTW Investments
Use of proceeds: Advance lead program MICVO through key clinical milestones including planned Phase 3 Headliner trial, plus working capital and general corporate purposes
Oct 2, 2026
Private placement of securities with accompanying warrants
Closed: US$50M raised
Use of proceeds: Advance MICVO through key clinical milestones and continue patient follow-up so data can mature
Aug 13, 2026
Private placement of common stock and warrants
Announced: about US$50M · US$2.551 a share · Warrants at US$3.289 · Wells Fargo Securities
Dealers: Wells Fargo Securities (lead)
Buyers: BVF Partners L.P. (led the financing); GordonMD Global Investments; RTW Investments; Coastlands Capital
Use of proceeds: Extend cash runway into Q2 2027 and advance lead clinical program MICVO through key clinical milestones
Jun 30, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Oct 7, 2021.

Price
US$16.00 a share
Shares offered
10,500,000 shares of common stock
Offering size
US$168 million
Underwriters' option
Up to 1,575,000 more shares
Underwriters
BofA Securities, Jefferies, Credit Suisse, William Blair, LifeSci Capital · In the order on the cover
Shares delivered
On or about Oct 13, 2021

Steps

StepWhen
Draft sent to the SEC in confidenceJun 21, 2021
Filed publiclySep 17, 2021
Amended 3 timesNewest Oct 7, 2021
Shares registered with an exchangeOct 5, 2021
Declared effective by the SECOct 7, 2021
Final prospectus, with the priceOct 8, 2021

Open IPO · From the cover of the final prospectus (424B4) filed Oct 8, 2021

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020
Revenue13.9M16.1M
Cost of revenue2.39M475.0K
Gross profit11.5M15.7M
Research and development73.7M58.7M49.6M86.1M51.1M9.05M
Operating income-84.4M-89.5M-82.2M-123.5M-69.7M-12.9M
Depreciation and amortization4.51M2.98M1.93M709.0K647.0K469.0K
EBITDA-79.9M-86.5M-80.3M-122.8M-69.1M-12.4M
Income before tax-78.2M-79.5M-73.8M
Income tax1.39M-2.16M
Net income-79.6M-77.3M-73.8M-120.7M-76.0M-12.8M
Earnings per share, basic-1.28-1.32-1.85-3.65-8.95-12.45
Earnings per share, diluted-1.28-1.32-1.85-3.65-8.95-12.45

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents15.4M19.5M9.66M179.3M274.7M8.08M
Short-term investments51.4M107.5M109.6M
Current assets72.1M132.4M124.6M186.6M278.7M8.10M
Property, plant and equipment8.00M9.90M11.9M11.2M1.01M1.10M
Total assets91.5M157.2M173.7M211.4M280.0M10.2M
Accounts payable10.9M4.86M3.90M7.10M12.0M1.08M
Current liabilities21.1M17.7M25.8M31.6M18.7M3.69M
Total liabilities38.1M36.4M48.0M50.6M18.7M3.85M
Shareholders' equity53.4M120.8M125.7M160.8M261.3M-15.6M
Shares outstanding62.7M60.0M44.8M35.0M32.2M1.29M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020
Cash from operations-63.5M-57.7M-70.7M-89.3M-35.3M-10.1M
Capital spending-9.00K-237.0K-6.73M-6.40M-540.0K-1.48M
Free cash flow-63.5M-57.9M-77.4M-95.7M-35.9M-11.6M
Cash from investing58.9M8.15M-104.8M-6.40M-590.0K-1.48M
Cash from financing594.0K59.3M5.93M183.0K304.0M35.0K
Change in cash-4.05M9.81M-169.6M-95.6M268.1M-11.5M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 19, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
8-K · Current reportNov 13, 2026Meeting outcomeSEC
4 · Change in ownershipNov 6, 2026Insider tradeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 3, 2026Big-stake noticeSEC
DEF 14A · Proxy statementOct 21, 2026Meeting noticeSEC
Show 200 filings
FilingDateTypeFiled with
PRE 14A · Preliminary proxy statementOct 9, 2026Meeting noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 9, 2026Big-stake noticeSEC
4/A · Change in ownership, amendedOct 9, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeOct 5, 2026Big-stake noticeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 2, 2026Big-stake noticeSEC
8-K · Current reportOct 1, 2026Material contractSEC
424B5 · ProspectusOct 1, 2026Offer documentSEC
424B5 · ProspectusSep 29, 2026Offer documentSEC
424B5 · ProspectusSep 29, 2026Offer documentSEC
8-K · Current reportSep 9, 2026Current reportSEC
4 · Change in ownershipSep 8, 2026Insider tradeSEC
8-K · Current reportSep 8, 2026Management or board changeSEC
424B2 · ProspectusAug 28, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 28, 2026Other filingsSEC
4 · Change in ownershipAug 20, 2026Insider tradeSEC
S-3 · Registration statementAug 20, 2026Offer documentSEC
4 · Change in ownershipAug 14, 2026Insider tradeSEC
10-Q · Quarterly reportAug 13, 2026Quarterly reportSEC
8-K · Current reportAug 13, 2026ResultsSEC
3 · Initial statement of ownershipJul 10, 2026Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJul 10, 2026Big-stake noticeSEC
4 · Change in ownershipJul 2, 2026Insider tradeSEC
8-K · Current reportJul 2, 2026Material contractSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 2, 2026Big-stake noticeSEC
144 · Notice of proposed saleJun 30, 2026Other filingsSEC
8-K · Current reportJun 15, 2026Meeting outcomeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
8-K · Current reportMay 14, 2026ResultsSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEFA14A · Additional proxy materialApr 30, 2026Meeting noticeSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
8-K/A · Current report, amendedApr 30, 2026Management or board changeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
4 · Change in ownershipMar 25, 2026Insider tradeSEC
S-8 · Registration statement for employee plansMar 23, 2026Offer documentSEC
10-K · Annual reportMar 23, 2026Annual reportSEC
8-K · Current reportMar 23, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 9, 2026Big-stake noticeSEC
8-K · Current reportFeb 6, 2026Current reportSEC
4 · Change in ownershipFeb 5, 2026Insider tradeSEC
8-K · Current reportDec 18, 2025Current reportSEC
EFFECT · Notice that a registration is effectiveDec 10, 2025Other filingsSEC
CORRESP · Letter to the SECDec 8, 2025Other filingsSEC
S-3 · Registration statementNov 26, 2025Offer documentSEC
10-Q · Quarterly reportNov 3, 2025Quarterly reportSEC
8-K · Current reportNov 3, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeSep 23, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 14, 2025Quarterly reportSEC
8-K · Current reportAug 14, 2025ResultsSEC
8-K · Current reportAug 4, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 17, 2025Big-stake noticeSEC
8-K · Current reportJul 2, 2025Management or board changeSEC
SCHEDULE 13G · Big-stake noticeJul 1, 2025Big-stake noticeSEC
8-K · Current reportJun 18, 2025Meeting outcomeSEC
10-Q · Quarterly reportMay 15, 2025Quarterly reportSEC
8-K · Current reportMay 15, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 6, 2025Big-stake noticeSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
144 · Notice of proposed saleApr 21, 2025Other filingsSEC
144 · Notice of proposed saleApr 17, 2025Other filingsSEC
144 · Notice of proposed saleApr 14, 2025Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedApr 2, 2025Big-stake noticeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
8-K · Current reportMar 24, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 18, 2025Offer documentSEC
10-K · Annual reportMar 18, 2025Annual reportSEC
8-K · Current reportMar 18, 2025ResultsSEC
8-K · Current reportFeb 26, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 14, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeFeb 4, 2025Big-stake noticeSEC
8-K · Current reportFeb 4, 2025Current reportSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 23, 2024Big-stake noticeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
8-K · Current reportDec 19, 2024Current reportSEC
SCHEDULE 13G · Big-stake noticeDec 16, 2024Big-stake noticeSEC
4 · Change in ownershipNov 27, 2024Insider tradeSEC
8-K · Current reportNov 20, 2024Current reportSEC
S-8 · Registration statement for employee plansNov 12, 2024Offer documentSEC
SC 13G/A · Big-stake notice, amendedNov 12, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
SC 13G/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
8-K · Current reportOct 23, 2024Meeting outcomeSEC
DEF 14A · Proxy statementSep 25, 2024Meeting noticeSEC
PRE 14A · Preliminary proxy statementSep 13, 2024Meeting noticeSEC
10-Q · Quarterly reportAug 14, 2024Quarterly reportSEC
8-K · Current reportAug 14, 2024ResultsSEC
8-K · Current reportJun 12, 2024Meeting outcomeSEC
4 · Change in ownershipJun 10, 2024Insider tradeSEC
3 · Initial statement of ownershipJun 10, 2024Insider tradeSEC
8-K · Current reportJun 10, 2024Management or board changeSEC
4 · Change in ownershipJun 7, 2024Insider tradeSEC
10-Q · Quarterly reportMay 14, 2024Quarterly reportSEC
8-K · Current reportMay 14, 2024ResultsSEC
ARS · Annual report to shareholdersApr 26, 2024Annual reportSEC
DEFA14A · Additional proxy materialApr 26, 2024Meeting noticeSEC
DEF 14A · Proxy statementApr 26, 2024Meeting noticeSEC
EFFECT · Notice that a registration is effectiveApr 4, 2024Other filingsSEC
424B2 · ProspectusApr 3, 2024Offer documentSEC
SC 13D/A · Big-stake notice, amendedApr 3, 2024Big-stake noticeSEC
CORRESP · Letter to the SECApr 1, 2024Other filingsSEC
UPLOAD · Letter from the SECMar 29, 2024Other filingsSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
4 · Change in ownershipMar 28, 2024Insider tradeSEC
S-3 · Registration statementMar 27, 2024Offer documentSEC
8-K · Current reportMar 27, 2024Current reportSEC
8-K · Current reportMar 27, 2024Current reportSEC
S-8 · Registration statement for employee plansMar 21, 2024Offer documentSEC
10-K · Annual reportMar 21, 2024Annual reportSEC
8-K · Current reportMar 21, 2024ResultsSEC
4 · Change in ownershipMar 13, 2024Insider tradeSEC
3 · Initial statement of ownershipMar 13, 2024Insider tradeSEC
8-K · Current reportMar 13, 2024Management or board changeSEC
SC 13G · Big-stake noticeMar 8, 2024Big-stake noticeSEC
8-K · Current reportFeb 28, 2024Material contractSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedFeb 14, 2024Big-stake noticeSEC
SC 13G · Big-stake noticeJan 26, 2024Big-stake noticeSEC
4 · Change in ownershipDec 29, 2023Insider tradeSEC
3 · Initial statement of ownershipDec 6, 2023Insider tradeSEC
4 · Change in ownershipNov 30, 2023Insider tradeSEC
8-K · Current reportNov 28, 2023Management or board changeSEC
4 · Change in ownershipNov 17, 2023Insider tradeSEC
10-Q · Quarterly reportNov 7, 2023Quarterly reportSEC
8-K · Current reportNov 7, 2023ResultsSEC
8-K/A · Current report, amendedOct 27, 2023Current reportSEC
4 · Change in ownershipSep 28, 2023Insider tradeSEC
4 · Change in ownershipSep 27, 2023Insider tradeSEC
4 · Change in ownershipSep 27, 2023Insider tradeSEC
4 · Change in ownershipSep 26, 2023Insider tradeSEC
4 · Change in ownershipSep 25, 2023Insider tradeSEC
4 · Change in ownershipSep 25, 2023Insider tradeSEC
4 · Change in ownershipSep 22, 2023Insider tradeSEC
4 · Change in ownershipSep 22, 2023Insider tradeSEC
4 · Change in ownershipSep 18, 2023Insider tradeSEC
144 · Notice of proposed saleSep 18, 2023Other filingsSEC
144 · Notice of proposed saleSep 14, 2023Other filingsSEC
4 · Change in ownershipSep 13, 2023Insider tradeSEC
144 · Notice of proposed saleSep 13, 2023Other filingsSEC
144 · Notice of proposed saleSep 12, 2023Other filingsSEC
144 · Notice of proposed saleSep 11, 2023Other filingsSEC
4 · Change in ownershipSep 8, 2023Insider tradeSEC
4 · Change in ownershipSep 8, 2023Insider tradeSEC
4 · Change in ownershipSep 8, 2023Insider tradeSEC
UPLOAD · Letter from the SECSep 6, 2023Other filingsSEC
144 · Notice of proposed saleSep 5, 2023Other filingsSEC
CORRESP · Letter to the SECAug 28, 2023Other filingsSEC
4 · Change in ownershipAug 25, 2023Insider tradeSEC
3 · Initial statement of ownershipAug 25, 2023Insider tradeSEC
EFFECT · Notice that a registration is effectiveAug 25, 2023Other filingsSEC
S-8 POSAug 23, 2023Offer documentSEC
POS AM · Amendment to an effective registrationAug 23, 2023Offer documentSEC
S-8 · Registration statement for employee plansAug 23, 2023Offer documentSEC
8-K · Current reportAug 23, 2023Acquisition or disposalSEC
UPLOAD · Letter from the SECAug 16, 2023Other filingsSEC
144 · Notice of proposed saleAug 11, 2023Other filingsSEC
10-Q · Quarterly reportAug 11, 2023Quarterly reportSEC
425Aug 11, 2023Other filingsSEC
8-K · Current reportAug 11, 2023ResultsSEC
425Aug 11, 2023Other filingsSEC

This page holds 200 of 362 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Pyxis Oncology, Inc.’s releases · as of Nov 4, 2026

Common shares
119,607,855
Fully diluted
119,607,855

Fully diluted

LineSharesAs of
Common shares119,607,855Nov 4, 2026

Warrants and options

Lot
Warrants · US$3.50 · expiry not stated

Share count over time

CountShares
Nov 4, 2026119,607,855

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
GordonMD Global Investments LP15.5M13.0%US$36.2MSep 30, 2026
Bvf Inc11.8M9.9%US$27.6MSep 30, 2026
Orbimed Advisors LLC8.36M7.0%US$19.5MSep 30, 2026
Pfizer Inc7.03M5.9%US$20.1MSep 30, 2026
Rtw Investments, LP6.51M5.4%US$15.2MSep 30, 2026
Laurion Capital Management LP4.99M4.2%US$11.6MSep 30, 2026
Vanguard4.42M3.7%US$10.3MSep 30, 2026
Longaeva Partners L.P.1.98M1.7%US$4.62MSep 30, 2026
Heights Capital Management, Inc1.25M1.0%US$2.91MSep 30, 2026
Wells Fargo1.12M0.93%US$2.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
BlackRock1.04M0.87%US$2.41MSep 30, 2026
Armistice Capital, LLC1.02M0.86%US$2.39MSep 30, 2026
Blue Owl Capital Holdings LP1M0.84%US$2.33MSep 30, 2026
Empery Asset Management, LP1M0.84%US$2.33MSep 30, 2026
Palo Alto Investors LP864K0.72%US$2.01MSep 30, 2026
Millennium832K0.70%US$1.94MSep 30, 2026
Marshall Wace, LLP760K0.64%US$1.77MSep 30, 2026
683 Capital Management, LLC714K0.60%US$1.66MSep 30, 2026
Geode Capital711K0.59%US$1.66MSep 30, 2026
Stonepine Capital Management, LLC689K0.58%US$1.61MSep 30, 2026
Sphera Funds Management LTD.689K0.58%US$1.61MSep 30, 2026
Atle Fund Management AB664K0.55%US$1.55MSep 30, 2026
Susquehanna548K0.46%US$1.28MSep 30, 2026
Hudson Bay Capital Management LP504K0.42%US$1.17MSep 30, 2026
Kingdon Capital Management, L.L.C.500K0.42%US$1.17MSep 30, 2026
LMR Partners LLP483K0.40%US$1.12MSep 30, 2026
Soros Fund Management LLC476K0.40%US$1.11MSep 30, 2026
Renaissance Technologies368K0.31%US$857KSep 30, 2026
DAFNA Capital Management LLC345K0.29%US$803KSep 30, 2026
Jacobs Levy Equity Management, Inc329K0.28%US$768KSep 30, 2026
State Street328K0.27%US$765KSep 30, 2026
Decheng Capital LLC327K0.27%US$761KSep 30, 2026
Highbridge Capital Management LLC229K0.19%US$665KSep 30, 2026
Monashee Investment Management LLC229K0.19%US$534KSep 30, 2026
Citadel198K0.17%US$462KSep 30, 2026
Schonfeld Strategic Advisors LLC152K0.13%US$355KSep 30, 2026
Goldman Sachs148K0.12%US$344KSep 30, 2026
BNY134K0.11%US$312KSep 30, 2026
Northern Trust124K0.10%US$289KSep 30, 2026
UBS122K0.10%US$284KSep 30, 2026
Bridgeway Capital Management, LLC108K0.09%US$251KSep 30, 2026
Empowered Funds, LLC93,8240.08%US$219KSep 30, 2026
Mackenzie90,7470.08%US$211KSep 30, 2026
Stifel Financial Corp77,6010.06%US$181KSep 30, 2026
Jump Financial, LLC64,2850.05%US$150KSep 30, 2026
Cable Car Capital, LP61,6060.05%US$144KSep 30, 2026
Commonwealth Equity Services, LLC48,7500.04%US$114KSep 30, 2026
University Of Chicago48,7310.04%US$114KSep 30, 2026
Two Sigma46,7000.04%US$109KSep 30, 2026
J. Derek Lewis & Associates Inc.44,0000.04%US$114KSep 30, 2026

This page holds 50 of 98 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.42M1.2%US$4.28MJun 30, 2026
Vanguard Extended Market Index Fund559K0.47%US$1.68MJun 30, 2026
iShares Biotechnology ETF375K0.31%US$1.13MJun 30, 2026
Fidelity Extended Market Index Fund272K0.23%US$489KMay 31, 2026
iShares Micro-Cap ETF167K0.14%US$501KJun 30, 2026
Fidelity Total Market Index Fund90,2760.08%US$162KMay 31, 2026
Fidelity Series Total Market Index Fund78,7090.07%US$142KMay 31, 2026
Ultra-Small Company Market Fund70,0600.06%US$211KJun 30, 2026
Fidelity Nasdaq Composite Index Fund38,0720.03%US$68,530May 31, 2026
Vanguard Balanced Index Fund26,8660.02%US$80,867Jun 30, 2026
All 17 holders
HolderSharesOf the companyValueAs of
Vanguard Institutional Total Stock Market Index Fund26,6500.02%US$80,217Jun 30, 2026
1290 VT Micro Cap Portfolio11,188<0.01%US$33,676Jun 30, 2026
U.S. Micro Cap Portfolio10,263<0.01%US$27,197Jul 31, 2026
Victory Extended Market Index Fund5,968<0.01%US$15,815Jul 31, 2026
JNL/DFA U.S. Small Cap Fund3,922<0.01%US$11,805Jun 30, 2026
Invesco Nasdaq Biotechnology ETF3,278<0.01%US$5,900May 31, 2026
ProShares Ultra Nasdaq Biotechnology2,303<0.01%US$4,145May 31, 2026

Insider trades

TradeTradeSharesPriceValueDate
GordonMD Global Investments LP
10% owner
Buy5,517,000Oct 1, 2026
Dupont Jakob
Director
Sale35,000USD 3.06US$107KJun 30, 2026

Big stakes

StakeStakeSharesDateFiling
GordonMD Global Investments LP16.40%20.4MOct 1, 2026Schedule 13G
Lara Sullivan, M.D.11.21%7.54MMar 31, 2025Schedule 13D
BVF PARTNERS L P/IL9.99%11.9MSep 30, 2026Schedule 13G
Rtw Investments, LP9.90%8.54MSep 30, 2026Schedule 13G
Coastlands Capital LP5.42%6.45MOct 1, 2026Schedule 13G
Laurion Capital Management LP5.16%4.3MSep 30, 2026Schedule 13G
Orbimed Advisors LLC3.60%4.35MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Freda Lewis-Hall
Other companies: CDT Equity Inc. (Director · Since at least Sep 22, 2023); SpringWorks Therapeutics Inc (Director · Since at least Mar 29, 2019); EXACT Sciences Corporation (Director · Apr 22, 2020 – Jun 8, 2023 · Past); 1Life Healthcare Inc (Director · Jan 30, 2020 – Feb 22, 2023 · Past); Pfizer, Inc. (Executive Vice President · Feb 22, 2018 – Feb 27, 2019 · Past)
Director · Since at least Oct 7, 2021
Darren Cline
Other companies: Xenon Pharmaceuticals Inc. (Chief Commercial Officer · Since at least Jun 23, 2025); Pliant Therapeutics, Inc. (Board Member · Since at least Jun 13, 2024)
Director · Since at least Mar 26, 2024
Rachel Humphrey
Other companies: Xilio Therapeutics, Inc. (Director · Oct 21, 2021 – Oct 21, 2021 · Past); Black Diamond Therapeutics, Inc. (Chief Medical Officer · Feb 17, 2021 – Feb 17, 2021 · Past)
Director · Since at least Aug 11, 2022
Michael A. Metzger
Other companies: Syndax Pharmaceuticals, Inc. (Chief Executive Officer and Director · Since at least Jul 16, 2025)
Director · Since at least Mar 31, 2025
Santhosh Palani
Other companies: Acrivon Therapeutics, Inc. (Director · Since at least Mar 4, 2024)
Director · Since at least Mar 12, 2024
Thomas Civik
Other companies: Repare Therapeutics Inc (Director · Since at least Jun 17, 2024)
Chief Executive Officer and Chairman of the Board · Since at least Mar 26, 2024
Alex KaneSenior Vice President, Investor Relations & Capital Markets · Oct 9, 2025 – Nov 5, 2026 · Past
Jakob DupontDirector · Since at least Jul 2, 2026
Jay FeingoldChief Medical Officer · Oct 7, 2021 – Mar 24, 2023 · Past
Jitendra WadhanePrin Fin & Acct Officer · Since at least Aug 3, 2022
All 15 people
PersonSeat
Joel EdwardsChief Business Officer · Oct 1, 2025 – Nov 5, 2026 · Past
John FlavinLead Independent Director · Since at least Nov 5, 2026
Nelson AzoulayChief Business Officer · Since at least May 7, 2026
Pyxis Oncology ContactPamela ConnealyCFO and COO · Feb 4, 2025 – Nov 5, 2026 · Past
Ronald HerbstChief Scientific Officer · Oct 7, 2021 – Oct 7, 2021 · Past

Open People

Log in to ask 6ix AI your own questions about Pyxis Oncology, Inc.